Niznik was initially reluctant to sell his holdings and forced Synergy to up its bid to the final £8 agreed after an initial offer of £7 at the end of October. Contact Us Whether you are CRO or Sponsor looking for a site network for your new clinical study, a physician wanting to develop a research department in your practice, or a patient interested in enrolling in one of our open clinical studies, please contact Synergy today. The stake was built later than Niznik’s but was being taken as early as 2003 so should have captured much of the upside. (THRA) The open-ended fund holds 1.5 million shares, amounting to 6.97% of the fund. Synergy CHC Corp., a consumer health care company, markets and distributes various consumer branded products primarily in the health and wellness industry. The other main beneficiary is AXA Framlington, which had a stake of around 18% before the Synergy offer, mainly held through George Luckraft’s equity income fund and Throgmorton investment trust. Synergy Healthcare Research Services Bradenton, Florida 276 followers Our expertise enables sponsors, CROs, and physicians to collaborate and complete more clinical trials. Niznik will sell off his entire holding of 610,000 shares, some 2.8% to Synergy. He bought at around £3, so has more than doubled his money.Īcross Standard Life’s funds the firm had a stake of around 13%. The stock was one of the holdings Citywire AAA-rated Mark Niznik launched the Standard Life UK Opportunities fund (Standard Life UK Opportunities-Life) with in 2002. This week Synergy secured acceptance from more than 90% of shareholders for its recommended bid for sterilisation plant provider Isotron. AXA Framlington and Standard Life Investment funds are the main beneficiaries of Synergy Healthcare’s buy-out of Isotron.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |